secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001104659-25-064755
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics appoints Robert C. Jahr as President and CEO, replacing interim CEO
--------------------------------------------------------------------------------

- Robert C. Jahr appointed President & CEO effective July 1, 2025; replaces interim CEO Lawrence Kenyon, who remains CFO and board member.
- Base salary $600,000; target annual bonus 70% of base; inducement option for 800,000 shares vesting over 4 years.
- Jahr previously Chief Commercial Officer at Sobi NA (2021-2025); held leadership roles at UCB Pharma and Amgen.
- Severance: 12 months base salary + target bonus on qualifying termination; 18 months base + 150% bonus on termination in connection with change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925064755/0001104659-25-064755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925064755/tm2519577d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-064755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer